研究交流：血清代谢组学特征预测早期肝细胞癌患者切除或消融后肿瘤复发

IF 6.7 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-08-26 DOI:10.1111/apt.70355

Ashwini Arvind, Hiroaki Kanzaki, Fouzia Ahmed, Naoto Fujiwara, Yujin Hoshida, Amit G. Singal

{"title":"研究交流：血清代谢组学特征预测早期肝细胞癌患者切除或消融后肿瘤复发","authors":"Ashwini Arvind, Hiroaki Kanzaki, Fouzia Ahmed, Naoto Fujiwara, Yujin Hoshida, Amit G. Singal","doi":"10.1111/apt.70355","DOIUrl":null,"url":null,"abstract":"Patients with hepatocellular carcinoma (HCC) often experience recurrence after curative therapies, underscoring a need for risk stratification models. We validated 6 and 13‐metabolite signatures in patients who achieved complete response following surgical resection or local ablation. Of 78 patients, 32 (41.0%) died and 40 (51.3%) experienced recurrence, of whom 35 (87.5%) had early recurrence. In multivariable analysis, the 6‐metabolite signature was associated with early recurrence (aHR 2.8, 95% CI 1.1–7.5), and the 13‐metabolite signature was associated with overall recurrence (aHR 2.5, 95% CI 1.1–6.0). These data support the potential role of serum metabolites in post‐treatment risk stratification for HCC recurrence.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"24 1","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma\",\"authors\":\"Ashwini Arvind, Hiroaki Kanzaki, Fouzia Ahmed, Naoto Fujiwara, Yujin Hoshida, Amit G. Singal\",\"doi\":\"10.1111/apt.70355\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients with hepatocellular carcinoma (HCC) often experience recurrence after curative therapies, underscoring a need for risk stratification models. We validated 6 and 13‐metabolite signatures in patients who achieved complete response following surgical resection or local ablation. Of 78 patients, 32 (41.0%) died and 40 (51.3%) experienced recurrence, of whom 35 (87.5%) had early recurrence. In multivariable analysis, the 6‐metabolite signature was associated with early recurrence (aHR 2.8, 95% CI 1.1–7.5), and the 13‐metabolite signature was associated with overall recurrence (aHR 2.5, 95% CI 1.1–6.0). These data support the potential role of serum metabolites in post‐treatment risk stratification for HCC recurrence.\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"24 1\",\"pages\":\"\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.70355\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70355","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

肝细胞癌（HCC）患者在治愈性治疗后经常出现复发，这强调了风险分层模型的必要性。我们在手术切除或局部消融后获得完全缓解的患者中验证了6和13‐代谢物特征。78例患者中死亡32例（41.0%），复发40例（51.3%），其中早期复发35例（87.5%）。在多变量分析中，6‐代谢物特征与早期复发相关（aHR为2.8,95% CI为1.1-7.5），13‐代谢物特征与总复发相关（aHR为2.5,95% CI为1.1-6.0）。这些数据支持血清代谢物在HCC复发治疗后风险分层中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma

Patients with hepatocellular carcinoma (HCC) often experience recurrence after curative therapies, underscoring a need for risk stratification models. We validated 6 and 13‐metabolite signatures in patients who achieved complete response following surgical resection or local ablation. Of 78 patients, 32 (41.0%) died and 40 (51.3%) experienced recurrence, of whom 35 (87.5%) had early recurrence. In multivariable analysis, the 6‐metabolite signature was associated with early recurrence (aHR 2.8, 95% CI 1.1–7.5), and the 13‐metabolite signature was associated with overall recurrence (aHR 2.5, 95% CI 1.1–6.0). These data support the potential role of serum metabolites in post‐treatment risk stratification for HCC recurrence.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.